| MDL | - |
|---|---|
| Molecular Weight | 268.27 |
| Molecular Formula | C15H12N2O3 |
| SMILES | O=C(C1=CC=CC=C1N)/C=C/C2=CC=CC([N+]([O-])=O)=C2 |
TMBIM6 antagonist-1 (BIA, 0.5-10 μM, 3 days) significantly and dose-dependently inhibits cell viability in HT1080, MCF7, MDA-MB-2341 and SKBR3 cells, with IC
50
values of 1.7 ± 0.1 μM for HT1080, 2.6 ± 0.4 μM for MCF cells, 2.6 ± 0.5 μM for MDA-MB-231 cells, and 2.4 ± 0.4 μM for SKBR3 cells, respectively
[1]
.
TMBIM6 antagonist-1 (BIA, 10 μM) treatment decreases cell migration in HT1080, MCF7, MDA-MB-231, and SKBR3 cells, not TMBIM6 KO HT1080 cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | HT1080, MCF7, MDA-MB-2341 and SKBR3 cells. |
| Concentration: | 0.5-10 μM. |
| Incubation Time: | 3 days. |
| Result: | Inhibited cell viability. |
Western Blot Analysis [1]
| Cell Line: | WT and TMBIM6 KO HT1080 cells. |
| Concentration: | 0, 2, 5 μM. |
| Incubation Time: | |
| Result: | Downregulated the protein levels of AKT-pS473. |
TMBIM6 antagonist-1 (1 mg/kg, IP 5 days per week during 25 days) significantly impaires cell-driven tumor growth
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: |
Six- to eight-week BklNbt:BALB/c/nu/nu old mice (HT1080 and MDA-MB-231 cells)
[1]
.
|
| Dosage: | 1 mg/kg. |
| Administration: | IP 5 days per week during 25 days. |
| Result: | Impaired cell-driven tumor growth. |
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : 50 mg/mL ( 186.38 mM ; Need ultrasonic)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.7276 mL | 18.6379 mL | 37.2759 mL |
| 5 mM | 0.7455 mL | 3.7276 mL | 7.4552 mL |
| 10 mM | 0.3728 mL | 1.8638 mL | 3.7276 mL |